Data have shown similar survival outcomes with 5 years of an aromatase inhibitor (“upfront” strategy) compared with treatment incorporating both tamoxifen and an aromatase inhibitor (“switch” strategy), but with a reduced risk of osteoporosis, fracture, and other side effects [27,28]. The gene discussed is CYP19A1; the disease is osteoporosis.